The FDA has approved Exdensur for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients aged 12 and older.
MedPage Today on MSN
GLP-1 Agents Tied to Less Risk of Asthma Exacerbations in Teens With Obesity
Adolescents with overweight or obesity and asthma taking a GLP-1 agent had less risk of asthma exacerbations compared with ...
Depemokimab-ulaa (Exdensur) has been approved by the US FDA as add-on maintenance therapy for severe asthma with an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback